NEW ORLEANS and SUNNYVALE, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced interim results from a Phase I/II study showing safety and clinical activity in patients with relapsed / recurrent non-Hodgkin's Lymphoma (NHL) treated with its HDAC inhibitor PCI-24781 as a single agent. The data were presented today at the 51st ASH Annual Meeting being held in New Orleans, LA (Abstract # 2726).
In a review of the clinical data at the end of the Phase I dose-escalation portion of the current lymphoma trial, it was revealed that PCI-24781 has shown strong signs of efficacy with minimal toxicity as a single agent in lymphoma, with 1 Complete Response (follicular lymphoma), 4 Partial Responses (2 follicular lymphoma, 1 diffuse large B-cell lymphoma, 1 mantle cell lymphoma) and 6 Stable Disease in 16 patients evaluated for response (after 2 cycles). Partial Response is defined as a 50% reduction in tumor size. The Overall Response Rate (Partial and Complete Response) has been 31%, with responses being observed in each of the four cohorts. Of 4 follicular lymphoma patients evaluated in this trial, 3 had objective responses (1 Complete Response and 2 Partial Responses).
"At completion of the Phase I stage of this clinical trial, PCI-24781 showed encouraging clinical activity as a mono-therapy in relapsed/refractory non-Hodgkin's lymphoma including several complete and partial remissions. Furthermore, due to its favorable side effect profile, pharmacokinetics, and large therapeutic window, it has the potential to be a class leader in the competitive HDAC inhibitor arena," said Dr. Andrew Evens, principal investigator of the study, and Assistant Professor of Medicine and Director of Translational Therapeutics in the Division of Hematology/Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.
About HDAC Inhibitors
About Non-Hodgkin's Lymphoma
Follicular lymphoma is a long lasting disease whereby patients are prone to multiple relapses after initial therapy; and the disease is incurable with current available treatments. Approximately 18,500 new cases of follicular lymphoma are diagnosed annually in the United States. According to the National Cancer Institute's SEER database the incidence of NHL (all types including Follicular and Aggressive) is projected at nearly 66,000 in 2009 and that 19,500 patients are expected to die from this disease in the United States in 2009. According to the Leukemia & Lymphoma Society (LLS), there are approximately 452,723 people in the U.S. living with NHL (with active disease or in remission).
Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.
CONTACT: Ramses Erdtmann, VP Finance of Pharmacyclics, Inc.,
+1-408-215-3325
Web site: http://www.pharmacyclics.com/
